secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2021-12-02T23:59:59+00:00
Accession:  0001104659-21-145714
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune appoints Christy Oliger to Board effective Dec 1, 2021
----------------------------------------------------------------

- Oliger appointed to Board, increasing size to 11; also joins Audit and R&D Committees.
- She brings ~30 yrs pharma/biotech experience, most recently SVP Oncology at Genentech.
- Receives $40k annual Board cash retainer, plus $7.5k Audit, $6k R&D; stock option for 33k shares at $28.01.
- Option vests 25% on 1st anniversary, then monthly over 24 months.
- Appointment effective Dec 1, 2021; will stand for election at 2022 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465921145714/0001104659-21-145714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465921145714/tm2134404d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-145714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer